Revelation Biosciences, Inc. (NASDAQ:REVB) Shares Shorted: Short Interest Up 517.6% in September

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 1,581 shares, a growth of 517.6% from the September 15th total of 256 shares. Based on an average trading volume of 36,220 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Revelation Biosciences Trading Down 1.8%

Shares of REVB opened at $0.76 on Friday. Revelation Biosciences has a 1-year low of $0.75 and a 1-year high of $5.96. The stock has a market capitalization of $3.02 million, a P/E ratio of -0.06 and a beta of -0.07. The business’s 50-day moving average price is $0.98 and its 200 day moving average price is $1.05.

Revelation Biosciences (NASDAQ:REVB) last issued its earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.01. On average, research analysts predict that Revelation Biosciences will post -5.18 earnings per share for the current year.

Institutional Trading of Revelation Biosciences

A hedge fund recently raised its stake in Revelation Biosciences stock. Sabby Management LLC increased its stake in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) by 192.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 605,702 shares of the company’s stock after purchasing an additional 398,651 shares during the quarter. Revelation Biosciences comprises about 0.7% of Sabby Management LLC’s portfolio, making the stock its 8th biggest position. Sabby Management LLC owned 8.78% of Revelation Biosciences worth $484,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 12.80% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Revelation Biosciences presently has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that activate and regulate the body’s innate immune system. Its research is aimed primarily at addressing infectious diseases and inflammatory conditions, particularly those affecting the respiratory system.

The company’s pipeline includes intranasal product candidates designed to stimulate localized immune responses in the nose and airways. Its lead candidate, REVTx-99, has been developed as an investigational therapy for respiratory conditions, including the prevention or reduction of complications associated with severe respiratory infections.